ALEXANDRIA, Va. – In a study of more than 1,100 people with COVID-19 undergoing treatment for cancer, researchers found lower COVID-19 vaccination rates among patients with comorbidities, metastatic solid tumors or non-B-cell hematologic malignancies, and those living in areas with lower education attainment and higher levels of unemployment. The study, funded by Conquer Cancer®, the ASCO Foundation, was published today in Cancer. 

Eight notable studies exploring new approaches in the treatment and management of genitourinary cancers will be presented at the 2023 ASCO Genitourinary Cancers Symposium, taking place February 16-18, 2023, at the Moscone West Building in San Francisco, California.  

The TALAPRO-2 phase III clinical trial found that a polymerase inhibitor combined with an androgen receptor inhibitor had significantly better progression-free survival (PFS) versus the current standard of care for people with metastatic, castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair pathway status. Homologous recombination repair involves a pathway that can help fix DNA double-strand breaks and cross-links between DNA strands.

Study participants with prostate cancer who reported the highest amounts of plant-based foods in their diets had a 52% lower risk of the cancer progressing and a 53% lower risk of recurrence compared to those who had the lowest amounts of plants in their diets. The diet assessments were based on questionnaires of food consumption given to people enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study.

In anticipation of President Biden’s State of the Union Address, the Association for Clinical Oncology (ASCO) is urging the president to keep cancer care and research as top national priorities. 

Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of the President and the resources of the federal government is essential to our shared goal of accelerating the pace of progress against a disease that will be diagnosed in more than 1.9 million people in the U.S. this year.

SAN FRANCISCO – Eleven noteworthy studies exploring new approaches in the treatment and management of gastrointestinal cancers will be presented at the 2023 ASCO Gastrointestinal Cancers Symposium, taking place January 19-21, 2023, at the Moscone West Building in San Francisco, California.